NCDM-32B
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527665

CAS#: 1239468-48-4

Description: NCDM-32B is a novel potent and selective KDM4 inhibitor, impairing viability and transforming phenotypes of basal breast cancer.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 405 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-03. Prices are subject to change without notice.

NCDM-32B, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 527665
Name: NCDM-32B
CAS#: 1239468-48-4
Chemical Formula: C15H30N2O4
Exact Mass: 302.2206
Molecular Weight: 302.415
Elemental Analysis: C, 59.58; H, 10.00; N, 9.26; O, 21.16


Synonym: NCDM-32B; NCDM32B; NCDM 32B

IUPAC/Chemical Name: Methyl 3-[9-(dimethylamino)nonanoyl-hydroxyamino]propanoate

InChi Key: KDYRPQNFCURCQB-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H30N2O4/c1-16(2)12-9-7-5-4-6-8-10-14(18)17(20)13-11-15(19)21-3/h20H,4-13H2,1-3H3

SMILES Code: O=C(OC)CCN(C(CCCCCCCCN(C)C)=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015 Mar 15;5(4):1519-30. eCollection 2015. PubMed PMID: 26101715; PubMed Central PMCID: PMC4473328.

2: Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, Aoki Y. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Hum Mol Genet. 2014 Dec 15;23(24):6553-66. doi: 10.1093/hmg/ddu376. Epub 2014 Jul 17. PubMed PMID: 25035421.